Previous Article in Journal
Cooperation between NMDA-Type Glutamate and P2 Receptors for Neuroprotection during Stroke: Combining Astrocyte and Neuronal Protection
Article Menu

Export Article

Open AccessArticle
Neuroglia 2018, 1(1), 6; https://doi.org/10.3390/neuroglia1010006

l-Dopa and Fluoxetine Upregulate Astroglial 5-HT2B Receptors and Ameliorate Depression in Parkinson’s Disease Mice

1,†
,
1,†
,
2,3
and
1,*
1
Laboratory of Metabolic Brain Diseases, Institute of Metabolic Disease Research and Drug Development, China Medical University, 110122 Shenyang, China
2
Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PT, UK
3
Achucarro Center for Neuroscience, IKERBASQUE, Basque Foundation for Science, 48011 Bilbao, Spain
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 19 March 2018 / Revised: 13 April 2018 / Accepted: 13 April 2018 / Published: 23 April 2018
View Full-Text   |   Download PDF [1247 KB, uploaded 3 May 2018]   |  

Abstract

Here, we report the association between depressive behavior (anhedonia) and astroglial expression of 5-hydroxytryptamine receptor 2B (5-HT2B) in an animal model of Parkinson’s disease, induced by bilateral injection of 6-hydroxydopamine (6-OHDA) into the striatum. Expression of the 5-HT2B receptor at the mRNA and protein level was decreased in the brain tissue of 6-OHDA-treated animals with anhedonia. Expression of the 5-HT2B receptor was corrected by four weeks treatment with either l-3,4-dihydroxyphenylalanine (l-dopa) or fluoxetine. Simultaneously, treatment with l-dopa abolished 6-OHDA effects on both depressive behavior and motor activity. In contrast, fluoxetine corrected 6-OHDA-induced depression but did not affect 6-OHDA-induced motor deficiency. In addition, 6-OHDA downregulated gene expression of the 5-HT2B receptor in astrocytes in purified cell culture and this downregulation was corrected by both l-dopa and fluoxetine. Our findings suggest that 6-OHDA-induced depressive behavior may be related to the downregulation of gene expression of the 5-HT2B receptor but 6-OHDA-induced motor deficiency reflects, arguably, dopamine depletion. Previously, we demonstrated that fluoxetine regulates gene expression in astrocytes by 5-HT2B receptor-mediated transactivation of epidermal growth factor receptor (EGFR). However, the underlying mechanism of l-dopa action remains unclear. The present work indicates that the decrease of gene expression of the astroglial 5-HT2B receptor may contribute to development of depressive behavior in Parkinson’s disease. View Full-Text
Keywords: 5-HT2B receptor; astrocytes; depressive behavior; Parkinson’s disease; fluoxetine 5-HT2B receptor; astrocytes; depressive behavior; Parkinson’s disease; fluoxetine
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Song, D.; Ma, K.; Verkhratsky, A.; Peng, L. l-Dopa and Fluoxetine Upregulate Astroglial 5-HT2B Receptors and Ameliorate Depression in Parkinson’s Disease Mice. Neuroglia 2018, 1, 6.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Neuroglia EISSN 2571-6980 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top